These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 27895501)

  • 1. A FISH-based method for assessment of
    Frithiof H; Aaltonen K; Rydén L
    Onco Targets Ther; 2016; 9():7095-7103. PubMed ID: 27895501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation.
    Frithiof H; Welinder C; Larsson AM; Rydén L; Aaltonen K
    J Transl Med; 2015 Apr; 13():126. PubMed ID: 25896421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-2 status of circulating tumor cells in a metastatic breast cancer cohort: A comparative study on characterization techniques.
    Brouwer A; De Laere B; van Dam PJ; Peeters D; Van Haver J; Sluydts E; El Moussaoui A; Mendelaar P; Kraan J; Peeters M; Van Laere S; Dirix L
    PLoS One; 2019; 14(9):e0220906. PubMed ID: 31483799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer.
    Flores LM; Kindelberger DW; Ligon AH; Capelletti M; Fiorentino M; Loda M; Cibas ES; Jänne PA; Krop IE
    Br J Cancer; 2010 May; 102(10):1495-502. PubMed ID: 20461092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status.
    Fehm T; Becker S; Duerr-Stoerzer S; Sotlar K; Mueller V; Wallwiener D; Lane N; Solomayer E; Uhr J
    Breast Cancer Res; 2007; 9(5):R74. PubMed ID: 17963511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation and characterization of circulating tumor cells using a novel workflow combining the CellSearch
    Neumann MH; Schneck H; Decker Y; Schömer S; Franken A; Endris V; Pfarr N; Weichert W; Niederacher D; Fehm T; Neubauer H
    Biotechnol Prog; 2017 Jan; 33(1):125-132. PubMed ID: 27126369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a marker independent isolation method for circulating tumor cells in esophageal adenocarcinoma.
    Philippron A; Depypere L; Oeyen S; De Laere B; Vandeputte C; Nafteux P; De Preter K; Pattyn P
    PLoS One; 2021; 16(5):e0251052. PubMed ID: 33961658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
    Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
    BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System.
    Xu L; Mao X; Imrali A; Syed F; Mutsvangwa K; Berney D; Cathcart P; Hines J; Shamash J; Lu YJ
    PLoS One; 2015; 10(9):e0138032. PubMed ID: 26397728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
    Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
    Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining.
    Campton DE; Ramirez AB; Nordberg JJ; Drovetto N; Clein AC; Varshavskaya P; Friemel BH; Quarre S; Breman A; Dorschner M; Blau S; Blau CA; Sabath DE; Stilwell JL; Kaldjian EP
    BMC Cancer; 2015 May; 15():360. PubMed ID: 25944336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.
    Pestrin M; Bessi S; Galardi F; Truglia M; Biggeri A; Biagioni C; Cappadona S; Biganzoli L; Giannini A; Di Leo A
    Breast Cancer Res Treat; 2009 Dec; 118(3):523-30. PubMed ID: 19597704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel approach using telomerase-specific replication-selective adenovirus for detection of circulating tumor cells in breast cancer patients.
    Kim SJ; Masago A; Tamaki Y; Akazawa K; Tsukamoto F; Sato J; Ozawa T; Tsujino Y; Noguchi S
    Breast Cancer Res Treat; 2011 Aug; 128(3):765-73. PubMed ID: 21630023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of HER2-positive Circulating Tumor Cells Using the LiquidBiopsy System in Breast Cancer.
    Chen W; Zhang J; Huang L; Chen L; Zhou Y; Tang D; Xie Y; Wang H; Huang C
    Clin Breast Cancer; 2019 Feb; 19(1):e239-e246. PubMed ID: 30472074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.
    Fehm T; Müller V; Aktas B; Janni W; Schneeweiss A; Stickeler E; Lattrich C; Löhberg CR; Solomayer E; Rack B; Riethdorf S; Klein C; Schindlbeck C; Brocker K; Kasimir-Bauer S; Wallwiener D; Pantel K
    Breast Cancer Res Treat; 2010 Nov; 124(2):403-12. PubMed ID: 20859679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer.
    Ligthart ST; Bidard FC; Decraene C; Bachelot T; Delaloge S; Brain E; Campone M; Viens P; Pierga JY; Terstappen LW
    Ann Oncol; 2013 May; 24(5):1231-8. PubMed ID: 23275633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A; Bronsard M; Lemieux R; Geha S
    Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.
    Mishima Y; Matsusaka S; Chin K; Mikuniya M; Minowa S; Takayama T; Shibata H; Kuniyoshi R; Ogura M; Terui Y; Mizunuma N; Hatake K
    Target Oncol; 2017 Jun; 12(3):341-351. PubMed ID: 28508152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.